Fulcrum positive phase 1b sickle cell trial results

 Fulcrum Therapeutics (FULC) on Saturday reported positive initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease.

“We are highly encouraged by these initial data from the 20 mg cohort, which show clear evidence of a dose-response and build on the strong profile established with the 12 mg cohort,” said Alex C. Sapir, Fulcrum’s President and Chief Executive Officer.

“At just six weeks of treatment, we have observed robust and clinically meaningful increases in fetal hemoglobin, with the majority of patients achieving absolute HbF levels ≥20%," Sapir added. 

Fulcrum Therapeutics (FULC) reported consistent early evidence of pan-cellular HbF induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis reduction.

https://www.msn.com/en-us/money/markets/fulcrum-therapeutics-shares-rise-after-positive-phase-1b-sickle-cell-trial-results/ar-AA1RVBV7